

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| |
|---------------------------------------|
| Name of entity HeraMED Limited |
| ABN 65 626 295 314 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|------------------|
| Name of Director | David Groberman |
| Date of last notice | 11 December 2018 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|--|
| Direct or indirect interest | Indirect |
| Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | Altshuler Shaham Trusts Ltd <David Groberman A/C> (beneficial holder) |
| Date of change | 28 November 2019 |
| No. of securities held prior to change | 7,995,723 Ordinary fully paid ordinary shares escrowed 24 months from quotation 3,187,500 Unlisted options @ \$0.25 expiring 5/12/21 escrowed 24 months from quotation 463,752 Unlisted options @ \$0.00002 expiring 5/12/21 escrowed 24 months from quotation |
| Class | Ordinary fully paid ordinary shares escrowed 24 months from quotation |
| Number acquired | 1,249,695 |

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|---|--|
| Number disposed | - |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | Deferred Consideration Shares issued to the vendors (and/or their nominees) as part of the Acquisition – refer Section 7.1(b)(ii) of the Prospectus dated 15/10/18. The securities have been issued upon meeting the performance milestone being receipt of the FDA approval, which was announced on 18/11/19. |
| No. of securities held after change | 9,245,418 Ordinary fully paid ordinary shares escrowed 24 months from quotation 3,187,500 Unlisted options @ \$0.25 expiring 5/12/21 escrowed 24 months from quotation 463,752 Unlisted options @ \$0.00002 expiring 5/12/21 escrowed 24 months from quotation |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Deferred Consideration Shares issued to the vendors (and/or their nominees) as part of the Acquisition – refer Section 7.1(b)(ii) of the Prospectus dated 15/10/18. The securities have been issued upon meeting the performance milestone being receipt of the FDA approval, which was announced on 18/11/19. |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

| | |
|--|-----|
| Detail of contract | N/A |
| Nature of interest | N/A |
| Name of registered holder (if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| Interest acquired | N/A |

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|--|-----|
| Interest disposed | N/A |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| Interest after change | N/A |

Part 3 – +Closed period

| | |
|--|-----|
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | N/A |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |

+ See chapter 19 for defined terms.